BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hong F, Xu P, Zhai Y. The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development. Int J Mol Sci 2018;19:E2189. [PMID: 30060458 DOI: 10.3390/ijms19082189] [Cited by in Crossref: 59] [Cited by in F6Publishing: 74] [Article Influence: 14.8] [Reference Citation Analysis]
Number Citing Articles
1 Geldhof V, de Rooij LPMH, Sokol L, Amersfoort J, De Schepper M, Rohlenova K, Hoste G, Vanderstichele A, Delsupehe AM, Isnaldi E, Dai N, Taverna F, Khan S, Truong AK, Teuwen LA, Richard F, Treps L, Smeets A, Nevelsteen I, Weynand B, Vinckier S, Schoonjans L, Kalucka J, Desmedt C, Neven P, Mazzone M, Floris G, Punie K, Dewerchin M, Eelen G, Wildiers H, Li X, Luo Y, Carmeliet P. Single cell atlas identifies lipid-processing and immunomodulatory endothelial cells in healthy and malignant breast. Nat Commun 2022;13:5511. [PMID: 36127427 DOI: 10.1038/s41467-022-33052-y] [Reference Citation Analysis]
2 Sood A, Qualls C, Murata A, Kroth PJ, Mao J, Schade DS, Murata G. Potential for repurposing oral hypertension/diabetes drugs to decrease asthma risk in obesity. J Asthma 2022;:1-12. [PMID: 35796615 DOI: 10.1080/02770903.2022.2097919] [Reference Citation Analysis]
3 Evans N, Conley JM, Cardon M, Hartig P, Medlock-Kakaley E, Gray LE Jr. In vitro activity of a panel of per- and polyfluoroalkyl substances (PFAS), fatty acids, and pharmaceuticals in peroxisome proliferator-activated receptor (PPAR) alpha, PPAR gamma, and estrogen receptor assays. Toxicol Appl Pharmacol 2022;449:116136. [PMID: 35752307 DOI: 10.1016/j.taap.2022.116136] [Reference Citation Analysis]
4 Sblano S, Cerchia C, Laghezza A, Piemontese L, Brunetti L, Leuci R, Gilardi F, Thomas A, Genovese M, Santi A, Tortorella P, Paoli P, Lavecchia A, Loiodice F. A chemoinformatics search for peroxisome proliferator-activated receptors ligands revealed a new pan-agonist able to reduce lipid accumulation and improve insulin sensitivity. European Journal of Medicinal Chemistry 2022;235:114240. [DOI: 10.1016/j.ejmech.2022.114240] [Reference Citation Analysis]
5 Lange NF, Graf V, Caussy C, Dufour JF. PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients. Int J Mol Sci 2022;23:4305. [PMID: 35457120 DOI: 10.3390/ijms23084305] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
6 Zhang B, Liu K, Yang H, Jin Z, Ding Q, Zhao L. Gut Microbiota: The Potential Key Target of TCM’s Therapeutic Effect of Treating Different Diseases Using the Same Method—UC and T2DM as Examples. Front Cell Infect Microbiol 2022;12:855075. [DOI: 10.3389/fcimb.2022.855075] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Gaspar JC, Okine BN, Dinneen D, Roche M, Finn DP. Effects of Intra-BLA Administration of PPAR Antagonists on Formalin-Evoked Nociceptive Behaviour, Fear-Conditioned Analgesia, and Conditioned Fear in the Presence or Absence of Nociceptive Tone in Rats. Molecules 2022;27:2021. [PMID: 35335382 DOI: 10.3390/molecules27062021] [Reference Citation Analysis]
8 Zhang J, Yang C, Qiu H, Yang J, Wu K, Ding S, Jiang C, Jiang Q. 14,15-EET involved in the development of diabetic cardiac hypertrophy mediated by PPARs. Prostaglandins & Other Lipid Mediators 2022. [DOI: 10.1016/j.prostaglandins.2022.106620] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Li J, Quan X, Zhang Y, Yu T, Lei S, Huang Z, Wang Q, Song W, Yang X, Xu P. PPARγ Regulates Triclosan Induced Placental Dysfunction. Cells 2021;11:86. [PMID: 35011648 DOI: 10.3390/cells11010086] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Li Z, Ren Q, Zhou Z, Cai Z, Wang B, Han J, Zhang L. Discovery of the first-in-class dual PPARδ/γ partial agonist for the treatment of metabolic syndrome. Eur J Med Chem 2021;225:113807. [PMID: 34455359 DOI: 10.1016/j.ejmech.2021.113807] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Martin WP, Chuah YHD, Conroy E, Reynolds AL, Judge C, López-Hernández FJ, le Roux CW, Docherty NG. Protocol for a preclinical systematic review and meta-analysis of pharmacological targeting of peroxisome proliferator-activated receptors in experimental renal injury. BMJ Open Sci 2021;5:e100240. [PMID: 34849404 DOI: 10.1136/bmjos-2021-100240] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Hou D, Liu F, Ren X, Shen Q, Zhou S. Protective mechanism of mung bean coat against hyperlipidemia in mice fed with a high-fat diet: insight from hepatic transcriptome analysis. Food Funct 2021. [PMID: 34792057 DOI: 10.1039/d1fo02455h] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
13 Wang C, Peng F, Zhong B, Shi Y, Wang X, Jin X, Niu J. Metabolomic Analysis Reveals the Therapeutic Effects of MBT1805, a Novel Pan-Peroxisome Proliferator-Activated Receptor Agonist, on α-Naphthylisothiocyanate-Induced Cholestasis in Mice. Front Pharmacol 2021;12:732478. [PMID: 34776958 DOI: 10.3389/fphar.2021.732478] [Reference Citation Analysis]
14 Kisoh K, Sugahara G, Ogawa Y, Furukawa S, Ishida Y, Okanoue T, Kohara M, Tateno C. Estimating Drug Efficacy with a Diet-Induced NASH Model in Chimeric Mice with Humanized Livers. Biomedicines 2021;9:1647. [PMID: 34829876 DOI: 10.3390/biomedicines9111647] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Xi Y, Xu PF. Diabetes and gut microbiota. World J Diabetes 2021; 12(10): 1693-1703 [PMID: 34754371 DOI: 10.4239/wjd.v12.i10.1693] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
16 Porcuna J, Mínguez-Martínez J, Ricote M. The PPARα and PPARγ Epigenetic Landscape in Cancer and Immune and Metabolic Disorders. Int J Mol Sci 2021;22:10573. [PMID: 34638914 DOI: 10.3390/ijms221910573] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Han L, Yang HY, Zheng YJ, Wei XX, Dan WC, Zhang LL, Ding QY, Ma X, Wang XM, Zhao LH, Tong XL. Mechanism exploration of Gouqi-wentang formula against type 2 diabetes mellitus by phytochemistry and network pharmacology-based analysis and biological validation. Chin Med 2021;16:93. [PMID: 34579756 DOI: 10.1186/s13020-021-00479-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Zhang X, Deng F, Zhang Y, Zhang X, Chen J, Jiang Y. PPARγ attenuates hepatic inflammation and oxidative stress of non‑alcoholic steatohepatitis via modulating the miR‑21‑5p/SFRP5 pathway. Mol Med Rep 2021;24:823. [PMID: 34558644 DOI: 10.3892/mmr.2021.12463] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Li J, Quan X, Lei S, Huang Z, Wang Q, Xu P. PFOS Inhibited Normal Functional Development of Placenta Cells via PPARγ Signaling. Biomedicines 2021;9:677. [PMID: 34203907 DOI: 10.3390/biomedicines9060677] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
20 Gao L, Wang L, Woo E, He X, Yang G, Bowlus C, Leung PSC, Gershwin ME. Clinical Management of Primary Biliary Cholangitis-Strategies and Evolving Trends. Clin Rev Allergy Immunol. 2019;. [PMID: 31713023 DOI: 10.1007/s12016-019-08772-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
21 Gaspar JC, Healy C, Ferdousi MI, Roche M, Finn DP. Pharmacological Blockade of PPARα Exacerbates Inflammatory Pain-Related Impairment of Spatial Memory in Rats. Biomedicines 2021;9:610. [PMID: 34072060 DOI: 10.3390/biomedicines9060610] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
22 Pinto C, Ibáñez MR, Loyola G, León L, Salvatore Y, González C, Barraza V, Castañeda F, Aldunate R, Contreras-Porcia L, Fuenzalida K, Bronfman FC. Characterization of an Agarophyton chilense Oleoresin Containing PPARγ Natural Ligands with Insulin-Sensitizing Effects in a C57Bl/6J Mouse Model of Diet-Induced Obesity and Antioxidant Activity in Caenorhabditis elegans. Nutrients 2021;13:1828. [PMID: 34071972 DOI: 10.3390/nu13061828] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Li H, Guan Y, Han C, Zhang Y, Liu Q, Wei W, Ma Y. The pathogenesis, models and therapeutic advances of primary biliary cholangitis. Biomed Pharmacother 2021;140:111754. [PMID: 34044277 DOI: 10.1016/j.biopha.2021.111754] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Tilekar K, Hess JD, Upadhyay N, Bianco AL, Schweipert M, Laghezza A, Loiodice F, Meyer-Almes FJ, Aguilera RJ, Lavecchia A, C S R. Thiazolidinedione "Magic Bullets" Simultaneously Targeting PPARγ and HDACs: Design, Synthesis, and Investigations of their In Vitro and In Vivo Antitumor Effects. J Med Chem 2021;64:6949-71. [PMID: 34006099 DOI: 10.1021/acs.jmedchem.1c00491] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
25 Cheng HS, Yip YS, Lim EKY, Wahli W, Tan NS. PPARs and Tumor Microenvironment: The Emerging Roles of the Metabolic Master Regulators in Tumor Stromal-Epithelial Crosstalk and Carcinogenesis. Cancers (Basel) 2021;13:2153. [PMID: 33946986 DOI: 10.3390/cancers13092153] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
26 Li G, Tan X, Zhang B, Guan L, Zhang Y, Yin L, Gao M, Zhu S, Xu L. Hengshun Aromatic Vinegar Improves Glycolipid Metabolism in Type 2 Diabetes Mellitus via Regulating PGC-1α/PGC-1β Pathway. Front Pharmacol 2021;12:641829. [PMID: 33981226 DOI: 10.3389/fphar.2021.641829] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Ramadan MS, Russo V, Nigro G, Durante-Mangoni E, Zampino R. Interplay between Heart Disease and Metabolic Steatosis: A Contemporary Perspective. J Clin Med 2021;10:1569. [PMID: 33917867 DOI: 10.3390/jcm10081569] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
28 Yang Z, Roth K, Agarwal M, Liu W, Petriello MC. The transcription factors CREBH, PPARa, and FOXO1 as critical hepatic mediators of diet-induced metabolic dysregulation. J Nutr Biochem 2021;95:108633. [PMID: 33789150 DOI: 10.1016/j.jnutbio.2021.108633] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
29 Ribeiro RFN, Cavadas C, Silva MMC. Small-molecule modulators of the circadian clock: Pharmacological potentials in circadian-related diseases. Drug Discov Today 2021;26:1620-41. [PMID: 33781946 DOI: 10.1016/j.drudis.2021.03.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
30 Ortega MA, Fraile-Martínez O, Pekarek L, Alvarez-Mon MA, Asúnsolo Á, Sanchez-Trujillo L, Coca S, Buján J, Álvarez-Mon M, García-Honduvilla N, Sainz F. Defective expression of the peroxisome regulators PPARα receptors and lysogenesis with increased cellular senescence in the venous wall of chronic venous disorder. Histol Histopathol 2021;36:547-58. [PMID: 33645625 DOI: 10.14670/HH-18-322] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
31 Devan AR, Nair B, Kumar AR, Nath LR. An insight into the role of telmisartan as PPAR-γ/α dual activator in the management of nonalcoholic fatty liver disease. Biotechnol Appl Biochem 2021. [PMID: 33578449 DOI: 10.1002/bab.2123] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
32 Uddin MS, Rahman MM, Sufian MA, Jeandet P, Ashraf GM, Bin-Jumah MN, Mousa SA, Abdel-Daim MM, Akhtar MF, Saleem A, Amran MS. Exploring the New Horizon of AdipoQ in Obesity-Related Alzheimer's Dementia. Front Physiol 2020;11:567678. [PMID: 33584324 DOI: 10.3389/fphys.2020.567678] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
33 Dou X, Duerfeldt AS. Small-Molecule Modulation of PPARs for the Treatment of Prevalent Vascular Retinal Diseases. Int J Mol Sci 2020;21:E9251. [PMID: 33291567 DOI: 10.3390/ijms21239251] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
34 Conley JM, Lambright CS, Evans N, McCord J, Strynar MJ, Hill D, Medlock-Kakaley E, Wilson VS, Gray LE Jr. Hexafluoropropylene oxide-dimer acid (HFPO-DA or GenX) alters maternal and fetal glucose and lipid metabolism and produces neonatal mortality, low birthweight, and hepatomegaly in the Sprague-Dawley rat. Environ Int 2021;146:106204. [PMID: 33126064 DOI: 10.1016/j.envint.2020.106204] [Cited by in Crossref: 10] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
35 Francque S, Szabo G, Abdelmalek MF, Byrne CD, Cusi K, Dufour J, Roden M, Sacks F, Tacke F. Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors. Nat Rev Gastroenterol Hepatol 2021;18:24-39. [DOI: 10.1038/s41575-020-00366-5] [Cited by in Crossref: 68] [Cited by in F6Publishing: 67] [Article Influence: 34.0] [Reference Citation Analysis]
36 Mazur II, Drozdovska S, Andrieieva O, Vinnichuk Y, Polishchuk A, Dosenko V, Andreev I, Pickering C, Ahmetov II. PPARGC1A gene polymorphism is associated with exercise-induced fat loss. Mol Biol Rep 2020;47:7451-7. [PMID: 32910289 DOI: 10.1007/s11033-020-05801-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
37 Bil W, Zeilmaker M, Fragki S, Lijzen J, Verbruggen E, Bokkers B. Risk Assessment of Per- and Polyfluoroalkyl Substance Mixtures: A Relative Potency Factor Approach. Environ Toxicol Chem 2021;40:859-70. [PMID: 32729940 DOI: 10.1002/etc.4835] [Cited by in Crossref: 3] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
38 Haroun M. In Silico Design, Synthesis and Evaluation of Novel Series of Benzothiazole- Based Pyrazolidinediones as Potent Hypoglycemic Agents. MC 2020;16:812-25. [DOI: 10.2174/1573406416666191227113716] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
39 Molocea CE, Tsokanos FF, Herzig S. Exploiting common aspects of obesity and cancer cachexia for future therapeutic strategies. Curr Opin Pharmacol 2020;53:101-16. [PMID: 32871469 DOI: 10.1016/j.coph.2020.07.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
40 Zhou Q, Sun HJ, Liu SM, Jiang XH, Wang QY, Zhang S, Yu DH. Anti-inflammation effects of the total saponin fraction from Dioscorea nipponica Makino on rats with gouty arthritis by influencing MAPK signalling pathway. BMC Complement Med Ther 2020;20:261. [PMID: 32843018 DOI: 10.1186/s12906-020-03055-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
41 Ren Q, Deng L, Zhou Z, Wang X, Hu L, Xie R, Li Z. Design, synthesis, and biological evaluation of novel dual PPARα/δ agonists for the treatment of T2DM. Bioorganic Chemistry 2020;101:103963. [DOI: 10.1016/j.bioorg.2020.103963] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
42 Terraza-Aguirre C, Campos-Mora M, Elizondo-Vega R, Contreras-López RA, Luz-Crawford P, Jorgensen C, Djouad F. Mechanisms behind the Immunoregulatory Dialogue between Mesenchymal Stem Cells and Th17 Cells. Cells 2020;9:E1660. [PMID: 32664207 DOI: 10.3390/cells9071660] [Cited by in Crossref: 5] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
43 Dewidar B, Kahl S, Pafili K, Roden M. Metabolic liver disease in diabetes - From mechanisms to clinical trials. Metabolism 2020;111S:154299. [PMID: 32569680 DOI: 10.1016/j.metabol.2020.154299] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 21.0] [Reference Citation Analysis]
44 Kadayat TM, Shrestha A, Jeon YH, An H, Kim J, Cho SJ, Chin J. Targeting Peroxisome Proliferator-Activated Receptor Delta (PPARδ): A Medicinal Chemistry Perspective. J Med Chem 2020;63:10109-34. [DOI: 10.1021/acs.jmedchem.9b01882] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
45 Tu J, Zhu S, Li B, Xu G, Luo X, Jiang L, Yan X, Zhang R, Chen C. Gegen Qinlian Decoction Coordinately Regulates PPARγ and PPARα to Improve Glucose and Lipid Homeostasis in Diabetic Rats and Insulin Resistance 3T3-L1 Adipocytes. Front Pharmacol 2020;11:811. [PMID: 32595495 DOI: 10.3389/fphar.2020.00811] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
46 Westerman KE, Harrington S, Ordovas JM, Parnell LD. PhyteByte: identification of foods containing compounds with specific pharmacological properties. BMC Bioinformatics 2020;21:238. [PMID: 32522154 DOI: 10.1186/s12859-020-03582-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
47 Abenavoli L, Procopio AC, Fagoonee S, Pellicano R, Carbone M, Luzza F, Invernizzi P. Primary Biliary Cholangitis and Bile Acid Farnesoid X Receptor Agonists. Diseases 2020;8:E20. [PMID: 32532037 DOI: 10.3390/diseases8020020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
48 Pessoa EA, Convento MB, Castino B, Leme AM, de Oliveira AS, Aragão A, Fernandes SM, Carbonel A, Dezoti C, Vattimo MF, Schor N, Borges FT. Beneficial Effects of Isoflavones in the Kidney of Obese Rats Are Mediated by PPAR-Gamma Expression. Nutrients 2020;12:E1624. [PMID: 32492810 DOI: 10.3390/nu12061624] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
49 Li Z, Xu Y, Cai Z, Wang X, Ren Q, Zhou Z, Xie R. Discovery of novel dual PPARα/δ agonists based on benzimidazole scaffold for the treatment of non-alcoholic fatty liver disease. Bioorganic Chemistry 2020;99:103803. [DOI: 10.1016/j.bioorg.2020.103803] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
50 Ye P, Xi Y, Huang Z, Xu P. Linking Obesity with Colorectal Cancer: Epidemiology and Mechanistic Insights. Cancers (Basel) 2020;12:E1408. [PMID: 32486076 DOI: 10.3390/cancers12061408] [Cited by in Crossref: 8] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
51 Kang Z, Fan R. PPARα and NCOR/SMRT corepressor network in liver metabolic regulation. FASEB j 2020;34:8796-809. [DOI: 10.1096/fj.202000055rr] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
52 Xie Z, Gao G, Wang H, Li E, Yuan Y, Xu J, Zhang Z, Wang P, Fu Y, Zeng H, Song J, Hölscher C, Chen H. Dehydroabietic acid alleviates high fat diet-induced insulin resistance and hepatic steatosis through dual activation of PPAR-γ and PPAR-α. Biomed Pharmacother 2020;127:110155. [PMID: 32413669 DOI: 10.1016/j.biopha.2020.110155] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
53 Matheson J, Le Foll B. Therapeutic Potential of Peroxisome Proliferator-Activated Receptor (PPAR) Agonists in Substance Use Disorders: A Synthesis of Preclinical and Human Evidence. Cells 2020;9:E1196. [PMID: 32408505 DOI: 10.3390/cells9051196] [Cited by in Crossref: 6] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
54 Yao PL, Peavey J, Malek G. Leveraging Nuclear Receptors as Targets for Pathological Ocular Vascular Diseases.Int J Mol Sci. 2020;21. [PMID: 32326149 DOI: 10.3390/ijms21082889] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
55 Zhang XL, Wang YN, Ma LY, Liu ZS, Ye F, Yang JH. Uncarboxylated osteocalcin ameliorates hepatic glucose and lipid metabolism in KKAy mice via activating insulin signaling pathway. Acta Pharmacol Sin 2020;41:383-93. [PMID: 31659239 DOI: 10.1038/s41401-019-0311-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
56 Gaspar JC, Okine BN, Llorente-Berzal A, Roche M, Finn DP. Pharmacological Blockade of PPAR Isoforms Increases Conditioned Fear Responding in the Presence of Nociceptive Tone. Molecules 2020;25:E1007. [PMID: 32102354 DOI: 10.3390/molecules25041007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
57 Xi Y, Zhang Y, Zhu S, Luo Y, Xu P, Huang Z. PPAR-Mediated Toxicology and Applied Pharmacology. Cells 2020;9:E352. [PMID: 32028670 DOI: 10.3390/cells9020352] [Cited by in Crossref: 20] [Cited by in F6Publishing: 32] [Article Influence: 10.0] [Reference Citation Analysis]
58 Hurtevent A, Le Naour M, Leclerc V, Carato P, Melnyk P, Hennuyer N, Staels B, Beucher-Gaudin M, Caignard DH, Dacquet C, Lebegue N. Effect of 6-Benzoyl-benzothiazol-2-one scaffold on the pharmacological profile of α-alkoxyphenylpropionic acid derived PPAR agonists. J Enzyme Inhib Med Chem 2020;35:524-38. [PMID: 31939313 DOI: 10.1080/14756366.2020.1713771] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
59 Kytikova OY, Perelman JM, Novgorodtseva TP, Denisenko YK, Kolosov VP, Antonyuk MV, Gvozdenko TA. Peroxisome Proliferator-Activated Receptors as a Therapeutic Target in Asthma. PPAR Res 2020;2020:8906968. [PMID: 32395125 DOI: 10.1155/2020/8906968] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
60 Schubert M, Becher S, Wallert M, Maeß MB, Abhari M, Rennert K, Mosig AS, Große S, Heller R, Grün M, Lorkowski S. The Peroxisome Proliferator-Activated Receptor (PPAR)-γ Antagonist 2-Chloro-5-Nitro-N-Phenylbenzamide (GW9662) Triggers Perilipin 2 Expression via PPARδ and Induces Lipogenesis and Triglyceride Accumulation in Human THP-1 Macrophages. Mol Pharmacol 2020;97:212-25. [PMID: 31871304 DOI: 10.1124/mol.119.117887] [Cited by in Crossref: 3] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
61 Boeckmans J, Natale A, Rombaut M, Buyl K, Rogiers V, De Kock J, Vanhaecke T, M Rodrigues R. Anti-NASH Drug Development Hitches a Lift on PPAR Agonism. Cells 2019;9:E37. [PMID: 31877771 DOI: 10.3390/cells9010037] [Cited by in Crossref: 29] [Cited by in F6Publishing: 55] [Article Influence: 9.7] [Reference Citation Analysis]
62 Wen Q, Miao J, Lau N, Zhang C, Ye P, Du S, Mei L, Weng H, Xu Q, Liu X, Chen D, Zhang F, Li C, Li H. Rhein attenuates lipopolysaccharide-primed inflammation through NF-κB inhibition in RAW264.7 cells: targeting the PPAR-γ signal pathway. Can J Physiol Pharmacol 2020;98:357-65. [PMID: 31846359 DOI: 10.1139/cjpp-2019-0389] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
63 Cheng HS, Tan WR, Low ZS, Marvalim C, Lee JYH, Tan NS. Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence. Int J Mol Sci. 2019;20. [PMID: 31614690 DOI: 10.3390/ijms20205055] [Cited by in Crossref: 46] [Cited by in F6Publishing: 69] [Article Influence: 15.3] [Reference Citation Analysis]
64 Ruscica M, Busnelli M, Runfola E, Corsini A, Sirtori CR. Impact of PPAR-Alpha Polymorphisms-The Case of Metabolic Disorders and Atherosclerosis. Int J Mol Sci 2019;20:E4378. [PMID: 31489930 DOI: 10.3390/ijms20184378] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
65 Jarrar YB, Lee SJ. Molecular Functionality of Cytochrome P450 4 (CYP4) Genetic Polymorphisms and Their Clinical Implications. Int J Mol Sci 2019;20:E4274. [PMID: 31480463 DOI: 10.3390/ijms20174274] [Cited by in Crossref: 9] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
66 Rey F, Lesma E, Massihnia D, Ciusani E, Nava S, Vasco C, Al Haj G, Ghilardi G, Opocher E, Gorio A, Carelli S, Di Giulio AM. Adipose-Derived Stem Cells from Fat Tissue of Breast Cancer Microenvironment Present Altered Adipogenic Differentiation Capabilities. Stem Cells Int 2019;2019:1480314. [PMID: 31511776 DOI: 10.1155/2019/1480314] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
67 Hong F, Pan S, Guo Y, Xu P, Zhai Y. PPARs as Nuclear Receptors for Nutrient and Energy Metabolism. Molecules 2019;24:E2545. [PMID: 31336903 DOI: 10.3390/molecules24142545] [Cited by in Crossref: 38] [Cited by in F6Publishing: 64] [Article Influence: 12.7] [Reference Citation Analysis]
68 Ammazzalorso A, Maccallini C, Amoia P, Amoroso R. Multitarget PPARγ agonists as innovative modulators of the metabolic syndrome. European Journal of Medicinal Chemistry 2019;173:261-73. [DOI: 10.1016/j.ejmech.2019.04.030] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
69 Choi CI. Astaxanthin as a Peroxisome Proliferator-Activated Receptor (PPAR) Modulator: Its Therapeutic Implications. Mar Drugs 2019;17:E242. [PMID: 31018521 DOI: 10.3390/md17040242] [Cited by in Crossref: 19] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
70 Yamane M, Matono T, Okano JI, Nagahara R, Matsuki Y, Okamoto T, Miyoshi KI, Sugihara T, Nagahara T, Koda M, Isomoto H. Protective Effects of Ipragliflozin, a Sodium-glucose Cotransporter 2 Inhibitor, on a Non-alcoholic Steatohepatitis Mouse Model. Yonago Acta Med 2019;62:30-5. [PMID: 30962742 [PMID: 30962742 DOI: 10.33160/yam.2019.03.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
71 Alexopoulos AS, Qamar A, Hutchins K, Crowley MJ, Batch BC, Guyton JR. Triglycerides: Emerging Targets in Diabetes Care? Review of Moderate Hypertriglyceridemia in Diabetes. Curr Diab Rep 2019;19:13. [PMID: 30806837 DOI: 10.1007/s11892-019-1136-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
72 Forny-Germano L, De Felice FG, Vieira MNDN. The Role of Leptin and Adiponectin in Obesity-Associated Cognitive Decline and Alzheimer's Disease. Front Neurosci 2018;12:1027. [PMID: 30692905 DOI: 10.3389/fnins.2018.01027] [Cited by in Crossref: 48] [Cited by in F6Publishing: 80] [Article Influence: 16.0] [Reference Citation Analysis]
73 Bojková B, Kubatka P, Qaradakhi T, Zulli A, Kajo K. Melatonin May Increase Anticancer Potential of Pleiotropic Drugs. Int J Mol Sci 2018;19:E3910. [PMID: 30563247 DOI: 10.3390/ijms19123910] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
74 Zhang YF, Xu HM, Yu F, Wang M, Li MY, Xu T, Gao YY, Wang JX, Li PF. Crosstalk between MicroRNAs and Peroxisome Proliferator-Activated Receptors and Their Emerging Regulatory Roles in Cardiovascular Pathophysiology. PPAR Res 2018;2018:8530371. [PMID: 30622558 DOI: 10.1155/2018/8530371] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]